

Date: August 24, 2023

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of proposed incorporation of Wholly Owned subsidiary

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company in their meeting held today i.e. August 24, 2023 have approved the incorporation of a wholly owned subsidiary by the name Mankind Medicare Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs.

The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 for aforesaid is enclosed as annexure I.

The meeting of Board of Directors of the Company commenced at 4:40 p.m. (IST) and concluded at 5:05 p.m. (IST).

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711

Annexure I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	Name: Mankind Medicare Private Limited or any other name as may be approved by Registrar of Companies, Ministry of Corporate Affairs (Proposed WOS) Proposed initial authorized Capital: Rs. 5,00,00,000/- (Rupees Five Crore) Turnover: Not Applicable as yet to incorporate
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The proposed WOS once incorporated will be the related party of the Company Save and except what is mentioned above, the Promoters / promoter group / group companies are not interested in the transaction
3.	Industry to which the entity being acquired belongs	Pharmaceutical Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed WOS will be incorporated in India and shall carry out the business of manufacturing and production of various type of pharmaceutical dosage forms and consumer healthcare products which shall inter-alia include formulations, medical devices, packaging and other ancillary manufacturing and production activities
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	a. 100% subscription to initial paid up capital of Rs. 5,00,00,000/- (Rupees Five Crore only) is in cash b. Further investment of Rs. 25,00,00,000/- (Rupees Twenty Five Crore only) in one or more tranches as per business requirement, as may be decided by the authorized persons
8.	Cost of acquisition and/or the price at which the shares are acquired	As explained in point no. 7

MANKIND PHARMA LIMITED



9.	Percentage of shareholding / control acquired and / or number of shares acquired	100% subscription to the share capital
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable since the proposed WOS is yet to be incorporated

MANKIND PHARMA LIMITED